SPRY ARS Pharmaceuticals, Inc.
Price Chart
Executive Summary
ARS Pharmaceuticals announced FDA approval to remove age restrictions from the prescribing information for neffy 1 mg (epinephrine nasal spray), allowing children weighing ≥33 lbs. to use the needle-free treatment regardless of age. The label update also includes more flexible storage and usage guidance, which may improve patient adherence and expand market access.
Actionable Insight
The expanded label removes a major prescribing barrier for caregivers of young children, potentially accelerating adoption of neffy in pediatric settings. Traders should monitor future earnings for prescription growth trends and payer coverage updates.
Key Facts
- FDA approved removal of age restriction for neffy 1 mg, now available to all patients weighing ≥33 lbs., including children under 4 years old.
- Label update includes flexible storage: can be carried in blister pack or carrying case; company will include a free carrying case with each prescription starting summer 2026.
- Additional updates: neffy can be used after thawing if frozen, withstands temperatures up to 122°F, and sniffing after dosing does not alter treatment protocol.
- Approximately 25% of patients needing epinephrine are children ≥33 lbs. and <66 lbs., including ~25% under age 4 — a key underserved population due to needle fear.
Financial Impact
Expanded eligible patient population could increase market penetration; no direct revenue figures provided but addresses a key barrier to adoption.
Risk Factors
- Market acceptance still depends on payer reimbursement and competition from established epinephrine auto-injectors.
- Forward-looking statements about adoption and benefits are speculative and subject to execution risk.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263722 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 15, 2026
25d ago
|
8-K
| $7.43 $7.94 | ▲ +6.94% | ▲ +5.97% | $8.99 (+21.08%) |
|
May 15, 2026
25d ago
|
Press Release
| $7.43 $7.94 | ▼ −6.94% | ▼ −5.97% | $8.99 (−21.08%) |
|
May 13, 2026
27d ago
|
8-K
| $8.01 $7.17 | ▼ −10.49% | ▼ −9.33% | $8.99 (+12.23%) |
|
May 7, 2026
4w ago
|
Press Release
| $9.00 $8.01 | ▼ −11.00% | ▼ −12.50% | $8.99 (−0.11%) |
|
Mar 27, 2026
10w ago
|
Press Release
| $8.07 $8.39 | ▲ +3.97% | ▲ +0.10% | $8.99 (+11.40%) |
|
Mar 9, 2026
13w ago
|
Press Release
| $9.05 $8.70 | ▼ −3.87% | ▼ −2.51% | $8.99 (−0.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access